目的 探討阿加曲班注射液聯(lián)合依達(dá)拉奉治療急性缺血性腦梗死的臨床療效。方法 選取南京醫(yī)科大學(xué)附屬腦科醫(yī)院2012年7月-2013年6月收治的140例急性缺血性腦梗死患者，分為對(duì)照組（68例）和治療組（72例）。兩組患者均給予依達(dá)拉奉注射液30 mg/次，溶于100 mL生理鹽水30 min內(nèi)滴完，2次/d。在對(duì)照組基礎(chǔ)上，治療組前兩天給予阿加曲班注射液60 mg/d，溶于48 mL生理鹽水24 h靜脈滴注，其后給予阿加曲班注射液10 mg/d，溶于250 mL生理鹽水，分早晚2次持續(xù)滴注，3 h/次，共用藥7 d，兩組均治療14 d。比較兩組的血液流變學(xué)指標(biāo)、血凝指標(biāo)和生活質(zhì)量各項(xiàng)指標(biāo)。結(jié)果 治療后兩組各項(xiàng)血液流變學(xué)指標(biāo)均低于治療前，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組各項(xiàng)血液流變學(xué)指標(biāo)均低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后兩組的血凝指標(biāo)和生活質(zhì)量各項(xiàng)指標(biāo)均較治療前有所改善，且治療組優(yōu)于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 阿加曲班注射液聯(lián)合依達(dá)拉奉治療急性缺血性腦梗死具有顯著效果，值得臨床推廣。

Objective To explore the clinical efficacy of Argatroban Injection combined with edaravone in the treatment of acute ischemic cerebral infarction. Methods Patients (140 cases) with acute ischemic cerebral infarction, who came to Affiliated Nanjing Brain Hospital, Nanjing Medical University, from July 2012 to June 2013, were divided into control group (68 cases) and treatment group (72 cases). Patients in the two groups were given Edaravone Injection 30 mg/time, which was dissolved in saline 100 mL and was dripped completely within 30 min, twice daily. On the basis of the control group, patients in the treatment group were given Argatroban Injection 60 mg/d, which was dissolved in saline 48 mL and was iv completely within 24 h on two days before. And then they were given Argatroban Injection 10 mg/d, which was dissolved in saline 250 mL and was continuously dripped twice in the morning and evening, 3 h/time, for 7 d. The patients accepted the treatment for 14 d. The hemodynamics, blood coagulation, and quality of life indexes in the two groups were compared. Results After the treatment, the hemodynamic indexes in the two groups were lower than those before the treatment with significant difference (P < 0.05). And the hemodynamic indexes in the treatment group were lower than those in the control group with significant difference (P < 0.05). After the treatment, the blood coagulation and quality of life indexes in the two groups were improved compared with those before the treatment. And the blood coagulation and quality of life indexes in the treatment group were better than those in the control group with significant difference (P < 0.05). Conclusion Argatroban Injection combined with edaravone in the treatment of acute ischemic cerebral infarction has a good clinical efficacy, which is worthy of clinical application.